TY - JOUR
T1 - The global impact of SARS-CoV-2 in 181 people with cystic fibrosis
AU - McClenaghan, Elliot
AU - Cosgriff, Rebecca
AU - Brownlee, Keith
AU - Ahern, Susannah
AU - Burgel, Pierre Régis
AU - Byrnes, Catherine A.
AU - Colombo, Carla
AU - Corvol, Harriet
AU - Cheng, Stephanie Y.
AU - Daneau, Géraldine
AU - Elbert, Alexander
AU - Faro, Albert
AU - Goss, Christopher H.
AU - Gulmans, Vincent
AU - Gutierrez, Hector
AU - de Monestrol, Isabelle
AU - Jung, Andreas
AU - Justus, Lutz Nährlich
AU - Kashirskaya, Nataliya
AU - Marshall, Bruce C.
AU - McKone, Edward
AU - Middleton, Peter G.
AU - Mondejar-Lopez, Pedro
AU - Pastor-Vivero, M. Dolores
AU - Padoan, Rita
AU - Rizvi, Samar
AU - Ruseckaite, Rasa
AU - Salvatore, Marco
AU - Stephenson, Anne L.
AU - Filho, Luiz Vicente R.da Silva
AU - Melo, Joel
AU - Zampoli, Marco
AU - Carr, Siobhán B.
N1 - Publisher Copyright:
© 2020 European Cystic Fibrosis Society
PY - 2020/11
Y1 - 2020/11
N2 - With the growing SARS-CoV-2 pandemic, we need to better understand its impact in specific patient groups like those with Cystic Fibrosis (CF). We report on 181 people with CF (32 post-transplant) from 19 countries diagnosed with SARS-CoV-2 prior to 13 June 2020. Infection with SARS-CoV-2 appears to exhibit a similar spectrum of outcomes to that seen in the general population, with 11 people admitted to intensive care (7 post-transplant), and 7 deaths (3 post-transplant). A more severe clinical course may be associated with older age, CF-related diabetes, lower lung function in the year prior to infection, and having received an organ transplant. Whilst outcomes in this large cohort are better than initially feared overall, possibly due to a protective effect of the relatively younger age of the CF population compared to other chronic conditions, SARS-CoV-2 is not a benign disease for all people in this patient group.
AB - With the growing SARS-CoV-2 pandemic, we need to better understand its impact in specific patient groups like those with Cystic Fibrosis (CF). We report on 181 people with CF (32 post-transplant) from 19 countries diagnosed with SARS-CoV-2 prior to 13 June 2020. Infection with SARS-CoV-2 appears to exhibit a similar spectrum of outcomes to that seen in the general population, with 11 people admitted to intensive care (7 post-transplant), and 7 deaths (3 post-transplant). A more severe clinical course may be associated with older age, CF-related diabetes, lower lung function in the year prior to infection, and having received an organ transplant. Whilst outcomes in this large cohort are better than initially feared overall, possibly due to a protective effect of the relatively younger age of the CF population compared to other chronic conditions, SARS-CoV-2 is not a benign disease for all people in this patient group.
KW - COVID-19
KW - Coronavirus
KW - Cystic fibrosis
KW - SARS-CoV-2
KW - Transplant
UR - http://www.scopus.com/inward/record.url?scp=85095876998&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095876998&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2020.10.003
DO - 10.1016/j.jcf.2020.10.003
M3 - Article
C2 - 33183965
AN - SCOPUS:85095876998
SN - 1569-1993
VL - 19
SP - 868
EP - 871
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - 6
ER -